Share

November 2019; 6 (6) EditorialOpen Access

Pembrolizumab as a treatment for PML?

Waiting for Godot

Renaud A. Du Pasquier
First published October 9, 2019, DOI: https://doi.org/10.1212/NXI.0000000000000629
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
920

Share

Article Information

vol. 6 no. 6 e629
DOI: 
https://doi.org/10.1212/NXI.0000000000000629
PubMed: 
31597694
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • First Published October 9, 2019.
Copyright & Usage: 
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Renaud A. Du Pasquier, MD
  1. Renaud A. Du Pasquier, MD
    2. Scientific Advisory Boards:

    1. Merck, Celgene, Sanofi

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Celgene, Roche

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Swiss National Foundation 320030-179531 Swiss Society for Multiple Sclerosis

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Division of Neurology, Department of Clinical Neurosciences, University Hospital of Lausanne, University of Lausanne, Switzerland.
  1. Correspondence
    Dr. Du Pasquier renaud.du-pasquier{at}chuv.ch
View Full Text

Article usage

Article usage: October 2019 to December 2022

AbstractFullPdfSource
Oct 2019420177Highwire
Nov 2019630183Highwire
Dec 2019510734Highwire
Jan 202029232Highwire
Feb 2020112628Highwire
Mar 2020210723Highwire
Apr 202009222Highwire
May 2020111426Highwire
Jun 202007421Highwire
Jul 202009521Highwire
Aug 202039219Highwire
Sep 202028914Highwire
Oct 202029430Highwire
Nov 202006520Highwire
Dec 202037417Highwire
Jan 202118732Highwire
Feb 202108113Highwire
Mar 2021110024Highwire
Apr 202126213Highwire
May 202105211Highwire
Jun 202105113Highwire
Jul 202114519Highwire
Aug 202117123Highwire
Sep 202105924Highwire
Oct 202105527Highwire
Nov 202104326Highwire
Dec 202129760Highwire
Jan 202208813Highwire
Feb 202205722Highwire
Mar 202204215Highwire
Apr 202214013Highwire
May 202205410Highwire
Jun 20220407Highwire
Jul 20220394Highwire
Aug 202207512Highwire
Sep 202204528Highwire
Oct 202205312Highwire
Nov 202208022Highwire
Dec 202215110Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me